CARDIFF, CA--(Marketwire - Jan 4, 2012) - NeuroPerspective has released its January issue, which reviews 2011 and previews 2012 for the CNS therapeutics sector.

The review of 2011 includes NeuroPerspective's annual awards, in such categories as:

Best and Worst News of 2011

Best and Worst Performances by a CEO

The Lazarus Award

Best VC Funding Deal

Highlights and Lowlights for the year are discussed, with particular attention devoted to: Drugs with nicotinic mechanisms, including those from Targacept (NASDAQ: [ TRGT ]) and EnVivo Pharmaceuticals; the maturation of the MS therapeutics sector; BioTie's aggressive growth strategy; the temporarily popular fad of industry/academic collaboration; Alexza Pharmaceuticals (NASDAQ: [ ALXA ]) and the FDA; NeuroSearch's shrinkage; and Geron's unconscionable exit from their long-awaited spinal cord injury trial.

Capsule summaries of events and 2012 prospects for 100 CNS-oriented companies are included in the January issue.

Other features include: Assessments of the CNS area funding and partnering environments during 2011 ('Starvation Rations in the NeuroGulag'), a year which saw a decrease in resources of 23% from 2010; a wishlist for the sector; reasons for optimism about the profile of CNS therapeutics in the pharma environment; and this month's Company Review, featuring BioTie.

NeuroPerspective is the independent, monthly review of the neurotherapeutics area. A one-year subscription is US$2200, delivered as a pdf via email. A three month trial subscription is US$700.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment ) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing, an annual compendium of all CNS R&D programs, since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.